• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cue Biopharma Inc. (Amendment)

    2/14/22 4:23:55 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUE alert in real time by email
    SC 13G/A 1 tm226230d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Cue Biopharma, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    22978P106
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    þ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No. 22978P106

     

    1 Names of reporting persons
    Corriente Advisors, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ☐
    (b) ☐
    3 SEC use only
     
    4 Citizenship or place of organization
    Delaware

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:

    5 Sole voting power
    0
    6 Shared voting power
    0
    7 Sole dispositive power
    0
    8 Shared dispositive power
    0
    9 Aggregate amount beneficially owned by each reporting person
    0
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    0.0%
    12 Type of reporting person (see instructions)
    OO
           

     

    2

     

     

    CUSIP No. 22978P106

     

    1 Names of reporting persons
    Corriente Master Fund II, LP
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) ¨
    3 SEC use only
     
    4 Citizenship or place of organization
    Cayman Islands
    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    0
    7 Sole dispositive power
    0
    8 Shared dispositive power
    0
    9 Aggregate amount beneficially owned by each reporting person
    0
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    0.0%
    12 Type of reporting person (see instructions)
    PN
           

     

    3

     

     

    CUSIP No. 22978P106

     

    1 Names of reporting persons
    Mark L. Hart III
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) ¨
    3 SEC use only
     
    4 Citizenship or place of organization
    United States of America

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:

    5 Sole voting power
    0
    6 Shared voting power
    0
    7 Sole dispositive power
    0
    8 Shared dispositive power
    0
    9 Aggregate amount beneficially owned by each reporting person
    0
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    0.0%
    12 Type of reporting person (see instructions)
    IN
           

     

    4

     

     

    Explanatory Note

     

    This Amendment No. 1 (this “Amendment”) amends, in its entirety, the statement on Schedule 13G originally filed on February 16, 2021 (the “Schedule 13G”) by the Reporting Persons (defined below). This Amendment reflects that, as of the date hereof, each Reporting Person has ceased to be the beneficial owner of more than 5% of any class of securities of the Issuer. This Amendment is the final amendment to the Schedule 13G.

     

    Item 1(a) Name of issuer:

     

    Cue Biopharma, Inc.

     

    Item 1(b) Address of issuer’s principal executive offices:

     

    21 Erie Street, Cambridge, Massachusetts 02139

     

    Item 2(a) Name of person filing:

     

    This Amendment is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”)

     

      i) Corriente Advisors, LLC (“Corriente Advisors”);

     

      ii) Corriente Master Fund II, LP (“Corriente Master Fund II”); and

     

      iii) Mark L. Hart III (“Mr. Hart”).

     

    This Amendment relates to shares of common stock of the Issuer, par value $0.001 per share (“Shares”), that were previously directly held by Corriente Master Fund II. Corriente Advisors acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II. Corriente Advisors may be deemed to indirectly beneficially own securities held by Corriente Master Fund II. Mr. Hart is the Chairman and Chief Executive Officer of Corriente Advisors. Mr. Hart may be deemed to indirectly beneficially own securities held by Corriente Master Fund II. As of the date hereof, none of the Reporting Persons beneficially own any Shares or warrants or options to purchase Shares.

     

    Each Reporting Person declares that neither the filing of this Amendment or the Schedule 13G nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any syndicate or group with respect to the Issuer or any securities of the Issuer.

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of each of the Reporting Persons is 1401 Foch St, Suite 100, Fort Worth, TX 76107.

     

    Item 2(c) Citizenship:

     

      i) Corriente Advisors is a Delaware limited liability company;

     

      ii) Corriente Master Fund II is a Cayman Islands limited partnership; and

     

      iii) Mr. Hart is a citizen of the United States of America.

     

    5

     

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    Item 2(e) CUSIP No.:

     

    22978P106

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ¨ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); 

     

      (e) ☑ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); 

     

      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); 

     

      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

     

      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); 

     

      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); 

     

      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). 
         
      If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    6

     

     

    Item 4.

    Ownership

     

    As of the date hereof, for each of the Reporting Persons:

     

      (a) Amount beneficially owned: 0
      (b) Percent of class: 0.0%
      (c) Number of shares as to which such person has:  
            (i)    Sole power to vote or direct the vote: 0
            (ii)   Shared power to vote or direct the vote: 0
            (iii)  Sole power to dispose or to direct the disposition of: 0
            (iv)  Shared power to dispose or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

    CORRIENTE ADVISORS, LLC  
       
    /s/ Matthew Gilman  
    Chief Financial Officer  

     

     

    CORRIENTE MASTER FUND II, LP  
     
    /s/ Matthew Gilman  
    Chief Financial Officer of Corriente Advisors, LLC, the Investment Manager of Corriente Master Fund II, LP  

     

     

    MARK L. HART III  
       
    /s/ Mark L. Hart III  

     

    8

     

     

    EXHBIT INDEX

     

     

    Exhibit   Page No.
    A.  Joint Filing Agreement   10

     

    9

     

    Get the next $CUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CUE

    DatePrice TargetRatingAnalyst
    3/13/2024$6.00Buy
    Jefferies
    6/26/2023$10.00Outperform
    Oppenheimer
    11/21/2022$7.00Overweight
    Piper Sandler
    1/13/2022$20.00Buy
    H.C. Wainwright
    1/3/2022$28.00Buy
    Craig Hallum
    More analyst ratings

    $CUE
    Financials

    Live finance-specific insights

    See more
    • Cue Biopharma to Host Business Update Call and Webcast

      BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1-844-826-3035International Investors:1-412-317-5195Conference ID:10199037Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 The live and archived webcast will also b

      4/14/25 5:02:00 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma to Host Business Update Call and Webcast

      BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company's approach to enhance near-term shareholder value by refocusing resourc

      8/13/24 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma to Host Business Update Call and Webcast

      BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional au

      4/2/24 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Cue Biopharma with a new price target

      Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00

      3/13/24 7:30:48 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Cue Biopharma with a new price target

      Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00

      6/26/23 7:24:09 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Cue Biopharma with a new price target

      Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00

      11/21/22 7:39:31 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cue Biopharma Inc.

      SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

      3/11/24 6:40:41 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cue Biopharma Inc.

      SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

      2/7/24 5:09:04 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cue Biopharma Inc.

      SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

      1/31/24 2:08:28 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Millar Kerri-Ann

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      3/25/25 4:00:10 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Baker Daniel G.

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      3/25/25 4:00:07 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Passeri Daniel R

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      3/25/25 4:00:09 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

      BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO). With an extensive background and proven expertise in strategic transactions, portfolio optimization and alliance management through her extensive tenure at Johnson & Johnson and Jansen, Ms. Warren will play a pivotal role in advancing Cue Biopharma's core corporate objectives following the company's recent business restructuring and autoimmune program prioritizati

      9/9/24 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

      BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in drug development, including strategic, scientific, clinical and regulatory leadership expertise. "We are pleased to have Dr. Garzone join our board of directors," said Daniel Passeri, chief executive

      4/25/23 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

      BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD). Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson. "We are very pleased to welcome Mr. Verheyen to our BOD and leverage his extensive experience and guidance as we seek to enhance and broaden Cue Bi

      4/12/23 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cue Biopharma to Host Virtual Investor Event on May 15, 2025

      Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will host a virtual investor event on Thursday, May 15, 2025 at 11:00 AM ET. To register, click here. The virtual event will feature key opinion leaders (KOLs) Richard DiPaolo, PhD (Saint Louis University) and And

      5/8/25 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

      BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in New York, May 7-8, 2025. During the fireside chat, Cue Biopharma will discuss progress on its programs from the Immuno-STAT™ platform including the CUE-100 series, CUE-401, and CUE-501, which was recently partnered with Boehringer Ingelheim for T cell mediated targeted depletion of specific B cells to

      5/5/25 10:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

      BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase an aggregate of 2,867,304 shares of

      4/14/25 10:23:10 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    SEC Filings

    See more

    $CUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form DEF 14A filed by Cue Biopharma Inc.

      DEF 14A - Cue Biopharma, Inc. (0001645460) (Filer)

      4/25/25 4:00:15 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Cue Biopharma Inc.

      DEFA14A - Cue Biopharma, Inc. (0001645460) (Filer)

      4/25/25 4:00:03 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Cue Biopharma Inc.

      8-K - Cue Biopharma, Inc. (0001645460) (Filer)

      4/15/25 4:48:23 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Passeri Daniel R bought $30,900 worth of shares (30,000 units at $1.03), increasing direct ownership by 22% to 164,578 units (SEC Form 4)

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      12/18/24 4:00:04 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care